Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 170 JPY -0.58% Market Closed
Market Cap: 15.3B JPY
Have any thoughts about
Healios KK?
Write Note

Healios KK
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Healios KK
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Healios KK
TSE:4593
Cost of Revenue
-ÂĄ98m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Cost of Revenue
-ÂĄ4.7B
CAGR 3-Years
-43%
CAGR 5-Years
-39%
CAGR 10-Years
-40%
PeptiDream Inc
TSE:4587
Cost of Revenue
-ÂĄ12.2B
CAGR 3-Years
-69%
CAGR 5-Years
-49%
CAGR 10-Years
-42%
Takara Bio Inc
TSE:4974
Cost of Revenue
-ÂĄ18.1B
CAGR 3-Years
-3%
CAGR 5-Years
-5%
CAGR 10-Years
-5%
Pharma Foods International Co Ltd
TSE:2929
Cost of Revenue
-ÂĄ12.7B
CAGR 3-Years
-19%
CAGR 5-Years
-42%
CAGR 10-Years
-34%
C
Cuorips Inc
TSE:4894
Cost of Revenue
-ÂĄ13.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Healios KK
Glance View

Market Cap
15.3B JPY
Industry
Biotechnology

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Intrinsic Value
142.38 JPY
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Healios KK's Cost of Revenue?
Cost of Revenue
-98m JPY

Based on the financial report for Sep 30, 2024, Healios KK's Cost of Revenue amounts to -98m JPY.

What is Healios KK's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-654%

Over the last year, the Cost of Revenue growth was -654%.

Back to Top